Tyvaso

NYHA Functional Class III, refractory to conventional therapy, NYHA class IV + 2 more

Treatment

20 Active Studies for Tyvaso

Treatment for

NYHA Functional Class III

What is Tyvaso

TreprostinilThe Generic name of this drug

Treatment SummaryTreprostinil is a medication that mimics prostacyclin, a natural chemical produced by the body. It is used to treat pulmonary hypertension, a type of high blood pressure in the lungs.

Remodulinis the brand name

image of different drug pills on a surface

Tyvaso Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Remodulin

Treprostinil

2002

Effectiveness

How Tyvaso Affects PatientsTreprostinil is a medicine used to relax the blood vessels in your lungs and body and stops platelets from sticking together. When taken, it can lower the pressure on your heart and increase the amount of blood it pumps out. Treprostinil can increase the chances of bleeding, and can cause low blood pressure or worsen the symptoms of pulmonary arterial hypertension. Taking treprostinil by inhalation may cause bronchospasms in people with asthma, COPD or bronchial hyperreactivity. When taken intravenously, it can cause complications and increase the risk of infection.

How Tyvaso works in the bodyTreprostinil is a medication used to treat pulmonary arterial hypertension. It works by widening your blood vessels and reducing the stickiness of platelets, which helps to lower your blood pressure. Treprostinil also helps to reduce inflammation in your body. To achieve this, it binds to and activates certain receptors in your cells, which leads to an increase in cAMP levels. This increase leads to the opening of potassium channels which eventually cause the blood vessels to widen.

When to interrupt dosage

The encouraged portion of Tyvaso is reliant upon the diagnosed ailment, including recalcitrant to standard therapy, Pulmonary Arterial Hypertension and NYHA class IV. The amount of dosage can be found in the table beneath, subject to the procedure of delivery (e.g. Solution or Inhalant).

Condition

Dosage

Administration

refractory to conventional therapy

2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg

, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Tablet, extended release - Oral, Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit

Pulmonary Hypertension

2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg

NYHA Functional Class III

2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg

Pulmonary Arterial Hypertension

2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg

NYHA class IV

2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg

Warnings

Tyvaso Contraindications

Condition

Risk Level

Notes

Severe Hepatic Impairment

Do Not Combine

There are 20 known major drug interactions with Tyvaso.

Common Tyvaso Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Treprostinil may increase the hypotensive activities of Amifostine.

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Treprostinil.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Treprostinil.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Treprostinil.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Treprostinil.

Tyvaso Toxicity & Overdose RiskTaking too much treprostinil may cause flushing, headache, nausea, vomiting, diarrhea, and low blood pressure. In some cases, patients may experience confusion or loss of consciousness. Studies have not shown any long-term effects on fertility or any increased risk of cancer or mutation.

image of a doctor in a lab doing drug, clinical research

Tyvaso Novel Uses: Which Conditions Have a Clinical Trial Featuring Tyvaso?

Currently, 54 active clinical trials are being conducted to examine the utility of Tyvaso in treating Pulmonary Arterial Hypertension, NYHA Functional Class III and Pulmonary Arterial Hypertension related conditions.

Condition

Clinical Trials

Trial Phases

NYHA Functional Class III

0 Actively Recruiting

refractory to conventional therapy

0 Actively Recruiting

Pulmonary Hypertension

26 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

NYHA class IV

0 Actively Recruiting

Pulmonary Arterial Hypertension

5 Actively Recruiting

Phase 1, Not Applicable, Phase 2